Long-term Prognosis of Docetaxel Combined with Carboplatin for Prostate Cancer and Its Influencing Factors
Objective To investigate the long-term prognosis of docetaxel combined with carboplatin for prostate cancer and its influencing factors.Methods The clinical data of 145 prostate cancer patients admitted to the First Affiliated Hospital of Henan University from March 2016 to March 2018 were retrospectively analyzed,and all of whom were treated with docetaxel combined with carboplatin.The 5 years prognosis of the patients and their influencing factors were collected and analyzed.Results Survival within 5 years after discharge was 62.07％(90/145)in 145 patients and was included in the good prognosis group,and death was 37.93％(55/145)in the poor prognosis group.The age and pre-treatment prostate-specific antigen(PSA)level and Gleason score of patients in the poor prognosis group were higher than those in the good prognosis group,and the pre-treatment hemoglobin concentration was lower than that in the good prognosis group,and the differences were statistically significant(P＜0.05).Advanced age and high pre-treatment PSA levels,high Gleason score and low hemoglobin concentration were independent risk factors for poor long-term prognosis in docetaxel combined with carboplatin for prostate cancer(P＜0.05).Conclusion The long-term prognosis of docetaxel combined with carboplatin for prostate cancer is good.Factors affecting the prognosis of patients include age and pre-treatment PSA level,Gleason score and hemoglobin level.
万方数据
维普
